Who
Mitchell Chan
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Regenxbio; Director, Avalo Therapeutics; Chief Financial Officer, Viela Bio.
In numbers
- Trades disclosed
- 30
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $145K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 2 Mar 2020
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $46K4,902 at $9.32 | filing |
| 1 Sep 2026filed 3 Sep 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $46K4,902 at $9.32 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $72K3,167 at $22.88 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $72K3,167 at $22.88 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,166 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,166 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,166 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,166 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —73,749 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —39,650 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —39,650 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —73,749 at $0.00 | filing |
| 1 Sep 2025filed 3 Sep 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $44K4,901 at $8.93 | filing |
| 17 Jun 2025filed 18 Jun 2025 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 28 Mar 2025filed 1 Apr 2025 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,167 at $0.00 | filing |
| 28 Mar 2025filed 1 Apr 2025 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,167 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —62,547 at $0.00 | filing |
| 16 Sep 2024filed 18 Sep 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —289,362 at $0.00 | filing |
| 16 Sep 2024filed 18 Sep 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —58,869 at $0.00 | filing |
| 13 Aug 2024filed 14 Aug 2024 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,600 at $0.00 | filing |
News
Head-To-Head Survey: Avalo Therapeutics (NASDAQ:AVTX) & Ascendis Pharma A/S (NASDAQ:ASND)AVTX · themarketsdaily.com · 22 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) versus Praxis Precision Medicines (NASDAQ:PRAX) Financial AnalysisAVTX · tickerreport.com · 16 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) Stock Falls 6.6% – Should You Sell?AVTX · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Mitchell Chan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.